ライフサイエンスコーパス: heart transplant

1 opathy is a key prognostic determinant after heart transplant.

2 , etiology of heart failure, and reoperative heart transplant.

3 erging adulthood (17-24 years) in kidney and heart transplant.

4 s, 1 (3%) patient died and 4 (13%) underwent heart transplant.

5 y of nonobstructive HCM patients progress to heart transplant.

6 i-A monoclonal antibody and complement after heart transplant.

7 tation and are not observed in patients with heart transplant.

8 tdischarge, 42 (38%) patients died and 2 had heart transplants.

9 s II-deficient, C57BL/6 recipients of BALB/c heart transplants.

10 organ transplants, such as kidney, lung, and heart transplants.

11 nvasive testing, has been used in monitoring heart transplants.

12 istocompatibility complex-mismatched ectopic heart transplants.

13 omprehensively evaluated among recipients of heart transplants.

14 ceived heterotopic, minor antigen-mismatched heart transplants.

15 graft rejection are high among recipients of heart transplants.

16 major histocompatibility complex-mismatched heart transplants.

17 ective application of this definition to 290 heart transplants.

18 49 United Network for Organ Sharing status 1 heart transplants (11%).

19 years; liver transplant, 465,296 life-years; heart transplant, 269,715 life-years; lung transplant, 6

20 the study period, there were 3672 pediatric heart transplants; 3306 (90%) had a LVEF reported.

21 .8%) underwent renal transplant; 58 (17.6%), heart transplant; 54 (16.4%), lung transplant; 34 (10.3%

22 Of the 16,573 who underwent a heart transplant, 8346 (50.36%) did so during the day an

23 Among the 454 patients who underwent heart transplant, 84 (18.5%) were ECCT.

24 istry of Transplant Recipients placed on the heart transplant active waitlist from 2004 to 2015.

25 aged 18 years or older) received their first heart transplant alone, and had at least one follow-up r

26 Heart transplant and CABG patients had similar rates of

27 ncies required to manage patients undergoing heart transplant and device implants.

28 ll make the use of VADs a superior option to heart transplant and even to medical management in many

29 BL/6 hearts (H-2K(b)) at 60-90 days post-C3H heart transplant and treated with anti-CD154 mAbs.

30 fully MHC-incompatible BALB/c (H-2K(d)/D(d)) heart transplant and were passively transfused with anti

31 jection of a kidney allograft, 17.1% after a heart transplant, and 43.8% in heart transplant recipien

32 No association was present for heart transplant, and lung transplant was associated wit

33 verter-defibrillator discharges, 2 underwent heart transplants, and 2 were resuscitated after cardiac

34 ng the search terms "cardiac transplant" or "heart transplant," and "statin" for a literature search.

35 Risk factors for NODM after heart transplant are similar to those reported in other

36 If heart transplants are preceded by skin grafts bearing bo

37 lmonary exercise testing from 87 consecutive heart transplant assessment patients and 18 healthy cont

38 ned from 822 consecutive patients undergoing heart transplant at Columbia University Medical Center b

39 ldren <18 years of age who were listed for a heart transplant between 1999 and 2006 were included.

40 (PTLD) in a study of 3170 pediatric primary heart transplants between 1993 and 2009 at 35 institutio

41 ged 18 to 64 receiving first-time orthotopic heart transplants between July 2006 and December 2013 we

42 enhances both acute and chronic rejection of heart transplants, but it is unclear how this inflammati

43 can contribute significantly to rejection of heart transplants by activation of complement and intera

44 LVAD explanted (recovered patients), and 24 heart transplant candidates (HTx)-and 97 healthy control

45 ned relatively stable, whereas the number of heart transplant candidates has risen.

46 This study identified 28,548 heart transplant candidates in the Organ Procurement and

47 nge in policies related to the management of heart transplant candidates presenting with INTERMACS pr

48 e analyzed mortality and morbidity in 33,073 heart transplant candidates registered on the United Net

49 The number of adult heart transplant candidates waiting at the most urgent s

50 Thirty heart transplant candidates with an estimated glomerular

51 sponse to the changing clinical phenotype of heart transplant candidates, heart allocation policies h

52 43/160) and 21% (n = 11/53) in the lung and heart transplant candidates, respectively.

53 improves waiting list survival for pediatric heart transplant candidates.

54 loped for the management of HCV-seropositive heart transplant candidates.

55 scopic complication occurred in the lung and heart transplant candidates.

56 Eligible heart-transplant candidates (aged >18 years) were random

57 nsidered as a treatment option for pediatric heart-transplant candidates and may serve as a bridge to

58 ention, coronary artery bypass grafting, and heart transplant capability as well as larger hospital b

59 for patients with advanced HF referred to a heart transplant center.

60 s and is currently used in a number of major heart transplant centers as a secondary therapy for reca

61 tre, randomised non-inferiority trial at ten heart-transplant centres in the USA and Europe.

62 There is no consensus within the heart transplant community about whether patients who us

63 h nondilated cardiomyopathy (CMP) listed for heart transplant compared with children with dilated CMP

64 Among the 414 heart transplants complicated by PGF, 354 (85.5%) recipi

65 death (n=12), progressive heart failure and heart transplant complications (n=5), or postoperatively

66 ients with AAD were compared with matched 30 heart transplant controls.

67 primary end point of all-cause mortality or heart transplant (death/transplant) during a median foll

68 iltration rate at the time of evaluation for heart transplant did not correlate with the degree of fi

69 literature had severe disease with death or heart transplant during the first year of life.

70 At 1 year, survival rates for heart transplants during the day were 88.0% vs 87.7% dur

71 Survival rates at 30 days for heart transplants during the day were 95.0% vs 95.2% dur

72 jor limitations with only approximately 2500 hearts transplanted each year.

73 A total of 240 heart transplant endomyocardial biopsies were assessed.

74 participants was selected to represent post-heart-transplant events, with and without acute rejectio

75 oup of patients included in the Scandinavian Heart Transplant Everolimus De Novo Study With Early Cal

76 before receiving a minor antigen-mismatched heart transplant exhibited potent DTH, T-cell proliferat

77 many, including implantable defibrillators, heart transplant, external defibrillation/therapeutic hy

78 allograft vasculopathy (CAV) contributes to heart transplant failure, yet its pathogenesis is incomp

79 ed out-of-hospital cardiac arrest (n=20), or heart transplant for advanced heart failure (n=12), 1.8%

80 comparable with 17,389 patients who received heart transplants for nonamyloid heart disease: 64% in n

81 All children </=21 years of age listed for heart transplant from 2011 to 2015 who received a TCS de

82 Of 4565 pediatric primary heart transplants from 1994 to 2013, 3741 had complete d

83 database was queried for isolated pediatric heart transplants from January 1, 1994, to December 31,

84 rospective study was performed for pediatric heart transplants from the United Network of Organ Shari

85 nt group compared to 32% (n = 79/245) in the heart transplant group and 27% (n = 43/160) and 21% (n =

86 In the heart transplant group, 8 (4.6%) patients had AF (group

87 Strikingly, the majority of accepted heart transplants (>170 d) were devoid of allograft vasc

88 In hypertrophic cardiomyopathy (HCM), heart transplant has been predominantly confined to pati

89 Several areas of pediatric heart transplant have had significant developments over

90 The sickest children among those listed for heart transplant (HT) are also at higher risk of post-tr

91 cial differences in long-term survival after heart transplant (HT) are well known.

92 Risk factors for early mortality after heart transplant (HT) have not been used for quantitativ

93 exercise testing is a class I indication for heart transplant (HT) listing in children.

94 mong those with heart failure, and poor post heart transplant (HT) outcomes.

95 and cardiovascular deconditioning that place heart transplant (HT) recipients at increased cardiovasc

96 We compared risk stratification of heart transplant (HT) recipients for early post-HT morta

97 Despite low risk of late rejection after heart transplant (HT), surveillance endomyocardial biops

98 ) is the major cause of late mortality after heart transplant (HT), there is a need to identify marke

99 dysfunction is a common finding early after heart transplant (HT).

100 the functional status (FS) of children after heart transplant (HT).

101 From 2004 to 2009, we identified 24 isolated heart transplant (HTx) and 10 H+LTx recipients in whom t

102 -hospital mortality after cholecystectomy in heart transplant (HTx) recipients.

103 roducing Enterobacteriaceae was performed in heart transplant (HTx), lung transplant (LTx), and mecha

104 r-old white man with a history of orthotopic heart transplant, immunosuppressed with low-dose cyclosp

105 apidly progressive cardiomyopathy, requiring heart transplant in 4.

106 rs of age with a diagnosis of CMP listed for heart transplant in the United States between July 2004

107 atients >/=18 years old listed for a primary heart transplant in the US before (July 1, 2004-July 11,

108 Heart transplants in all non-MHC categories ostensibly s

109 ts (2.2%) either received or were listed for heart transplant, including 20 with normal systolic func

110 ty and an elevated risk of acute and chronic heart transplant injury in humans.

111 ic role of graft-derived complement in human heart transplant injury, these correlations suggest that

112 Furthermore, hearts transplanted into CD40(-/-) mice prime weak CD8-c

113 cell responses and survive indefinitely, but hearts transplanted into Daf1(-/-)CD40(-/-) recipients u

114 Finally, hearts transplanted into gamma delta T cell-deficient mi

115 allografts survived long term, PDL1-/- donor hearts transplanted into wild-type bm12 mice exhibited a

116 AAD after heart transplant is a heterogeneous process characterize

117 Heart transplant is indicated when conservative surgery

118 nce of preserved systolic function, for whom heart transplant is the sole definitive therapeutic opti

119 Long-term survival of heart transplants is hampered by chronic rejection (CR).

120 center reports and with data from kidney and heart transplants (KTX and HTX).

121 Four thousand four hundred seventy-one heart transplants met the study inclusion criteria.

122 antigen (HLA)-mismatched heterotopic murine heart transplant model (HLA-A2 into HLA-A2-sensitized-C5

123 ated an MCT-1 inhibitor, AS2495674, in a rat heart transplant model and analyzed its underlying mecha

124 We have developed a murine heart transplant model that isolates the contributions o

125 In a heart transplant model we showed that macrophage-specifi

126 onists are potent suppressor cells, and in a heart transplant model, they promote long-term allograft

127 Here, using a murine heart transplant model, we determined that only a small

128 Using the bm12 into B6 heart transplant model, we investigated the functional s

129 ansplant vascular sclerosis (TVS) in our rat heart transplant model.

130 ations, using murine MHC-mismatched skin and heart transplant models, donor-derived drug-modified DCs

131 Fontan 1, 54 subjects (10%) have received a heart transplant (n = 23) or died without transplantatio

132 Heart transplant (n=43) and CABG patients were referred

133 for Organ Sharing) database was queried for heart transplants occurring between October 31, 1987, an

134 valence of hepatitis C infection (HCV) among heart transplant (OHT) recipients ranges from 7% to 18%.

135 study evaluated whether minority orthotopic heart transplant (OHT) recipients tend to be transplante

136 nitiation of mechanical circulatory support, heart transplant, or death.

137 ble left ventricular assist device (LVAD) or heart transplant, or experience myocardial recovery.

138 line characteristics and incident mortality, heart transplant, or nonelective cardiovascular hospital

139 y was to confirm a relationship between post-heart transplant outcomes and center experience and to d

140 etails vismodegib use in an immunosuppressed heart transplant patient receiving cyclosporine therapy.

141 Pediatric heart transplant patients (n=106) bridged to transplanta

142 We reviewed the records of 174 consecutive heart transplant patients and 122 double-lung transplant

143 h EMB for rejection surveillance in selected heart transplant patients and does not result in increas

144 denervation may have a protective effect for heart transplant patients in the post-operative setting.

145 Sixty heart transplant patients meeting inclusion criteria wer

146 splant with EXCOR versus status 1A pediatric heart transplant patients not transplanted with ventricu

147 as in double-lung transplant patients versus heart transplant patients to gain insight into factors t

148 All heart transplant patients treated for symptomatic AMR se

149 Seventy-seven heart transplant patients underwent 118 subsequent anest

150 nt ischemia is likely to occur frequently in heart transplant patients with denervated hearts and cor

151 Of the 235 heart transplant patients, 24.7% had HLA antibodies, whe

152 ral drug ganciclovir prevents CMV disease in heart transplant patients, and valganciclovir and CMV im

153 antiviral therapy appears effective in D+/R- heart transplant patients, whereas in lung transplantati

154 ography were predictors of adverse events in heart transplant patients.

155 ing cause of late morbidity and mortality in heart transplant patients.

156 V adverse events occurred in 15 of 112 (13%) heart transplant patients.

157 odies in an international study of pediatric heart transplant patients.

158 However, a level of 10 to 12 heart transplants per year corresponds to the upper limi

159 ters to ensure volumes in excess of 10 to 12 heart transplants per year.

160 ears old) recipients of a primary orthotopic heart transplant performed between 2000 and 2012 were in

161 come of 1491 first isolated orthotopic adult heart transplants performed between April 1995 and March

162 Data on all single-organ heart transplants performed in the United States between

163 granzyme B SNPs (A-295G; Q-55R) in pediatric heart transplant (PHTx) recipients and (2) to determine

164 d late acute rejection episodes in pediatric heart transplant (PHTx) recipients.

165 c kidney disease (CKD) in the United Kingdom heart transplant population, identified risk factors for

166 ng cytomegalovirus infections in maintenance heart transplant populations.

167 ice insertion (heart failure samples) and at heart transplant (post-left ventricular assist device sa

168 CD4-deficient recipients of allogeneic heart transplants prime weak CD8 responses and do not ac

169 pective analysis of patients followed in the heart transplant program at Barnes Jewish Hospital from

170 early disseminated fungal infections in our heart transplant program, a retrospective analysis was c

171 establishing and directing the first Swedish heart transplant program.

172 ardiac transplantation, but low-volume adult heart transplant programs seem to have higher early mort

173 A total of 360 heart transplant providers responded from 26 countries.

174 diac mortality rate was 0.8%, and annualized heart transplant rate was 0.9%.

175 lationship persists among low- and high-risk heart transplant recipient-donor pairs.

176 in the development of PTLD in the pediatric heart transplant recipient.

177 In nonrejecting, otherwise healthy heart transplant recipients (>1 year after surgery, n=10

178 rtery flow-mediated dilation in 50 pediatric heart transplant recipients (8 to 17 years of age; 27 ma

179 T cells was performed retrospectively in 48 heart transplant recipients (HTR) and 42 kidney transpla

180 tis jirovecii pneumonia (PCP) occurred among heart transplant recipients (HTR) at the outpatient clin

181 Heart transplant recipients (n = 138) scheduled for rout

182 prospective clinical study including healthy heart transplant recipients 6 months to 25 years of age

183 Analysis included 8029 heart transplant recipients aged >/=18 years and transpl

184 Analysis included 19,593 orthotopic heart transplant recipients aged >or=18 years and transp

185 lain the discrepancy in AF incidence between heart transplant recipients and double-lung transplant r

186 ith invasive angiography in detecting CAV in heart transplant recipients and may be a preferable scre

187 e for replacing the endomyocardial biopsy in heart transplant recipients and may be applicable to oth

188 ed cell-free DNA circulating in the blood of heart transplant recipients and observed significantly i

189 hed (female donor heart to a male recipient) heart transplant recipients by a combination of chromoge

190 accurately diagnose acute rejection (AR) in heart transplant recipients could obviate the need for s

191 Half of heart transplant recipients develop chronic rejection wi

192 17.1% after a heart transplant, and 43.8% in heart transplant recipients developing transplant-relate

193 We retrospectively reviewed 329 heart transplant recipients followed up at our instituti

194 Serum samples were taken from pediatric heart transplant recipients for markers of inflammation

195 spective cohort study of 39075 adult primary heart transplant recipients from 1987 to 2009 using nati

196 Black heart transplant recipients have had persistently higher

197 r SED is associated with shorter survival in heart transplant recipients in England and should be con

198 We identified 10 943 adult (>/=18 years) heart transplant recipients in the United Network of Org

199 Nonwhite heart transplant recipients increased over time, compris

200 Chronic kidney disease among prior heart transplant recipients is a growing problem that is

201 Kidney graft survival among prior heart transplant recipients is inferior to KA1 but simil

202 is home blood pressure monitoring (HBPM) in heart transplant recipients is not known.

203 is home blood pressure monitoring (HBPM) in heart transplant recipients is not known.

204 A key determinant of long-term survival in heart transplant recipients is the development of corona

205 Analysis included heart transplant recipients more than or equal to 18 yea

206 aimed to test the hypothesis that pediatric heart transplant recipients of grafts with depressed ven

207 We prospectively monitored 617 heart transplant recipients referred from 4 French trans

208 Adult heart transplant recipients reported to the United Netwo

209 We prospectively tested in 30 heart transplant recipients the impact of Abs directed a

210 diac myosin (CM)-specific immunity on murine heart transplant recipients treated with donor-specific

211 ndomized studies, which compared outcomes in heart transplant recipients undergoing statin therapy to

212 -seropositive compared with HCV-seronegative heart transplant recipients using the Organ Procurement

213 n an open-label, 24-month trial, 721 de novo heart transplant recipients were randomized to everolimu

214 he paucity of data regarding the outcomes of heart transplant recipients who are HCV positive before

215 Sixty-three heart transplant recipients who had coronary physiology

216 scores have primarily been used to identify heart transplant recipients who have a low probability o

217 r block in healthy pediatric and young adult heart transplant recipients with minimal risk when low i

218 However, in pediatric heart transplant recipients with PRA greater than 50% or

219 e first preliminary study demonstrating that heart transplant recipients with preformed class II DSA

220 Furthermore, infection of rat heart transplant recipients with RCMV containing the r12

221 In heart transplant recipients, AF is uncommon and occurs i

222 cipients, 102 lung transplant recipients, 79 heart transplant recipients, and 15 recipients of other

223 with reduced cyclosporine dosing in de novo heart transplant recipients, in particular with everolim

224 on as seen long-term after "A-into-O" infant heart transplant recipients, normal anti-A antibody prod

225 In 105 heart transplant recipients, serial (baseline and 1-year

226 AD) is an important cause of morbidity among heart transplant recipients.

227 r HBPM adequately identifies hypertension in heart transplant recipients.

228 continues to limit the long-term survival of heart transplant recipients.

229 BPM is useful for the long-term follow-up of heart transplant recipients.

230 ostic marker for post-transplant survival in heart transplant recipients.

231 BPM is useful for the long-term follow-up of heart transplant recipients.

232 r HBPM adequately identifies hypertension in heart transplant recipients.

233 ves a reliable estimate of BP burden in most heart transplant recipients.

234 concentration on post-transplant outcome in heart transplant recipients.

235 igen bead assay before transplantation in 51 heart transplant recipients.

236 ntimal proliferation at 12 months in de novo heart transplant recipients.

237 fits and costs for BTT-VAD versus nonbridged heart transplant recipients.

238 dialysis treatment on subsequent survival in heart transplant recipients.

239 The majority occurred as late PTLD in male heart transplant recipients.

240 emerging as a strong predictor of outcome in heart transplant recipients.

241 ated with early microvascular dysfunction in heart transplant recipients.

242 und (IVUS) images of coronary arteries in 33 heart transplant recipients.

243 minate between CAV-negative and CAV-positive heart transplant recipients.

244 osis of antibody-mediated rejection (AMR) in heart transplant recipients.

245 lografts and with coronary artery disease in heart transplant recipients.

246 resence of acute cellular rejection in these heart transplant recipients.

247 with atherosclerosis and graft rejection in heart transplant recipients.

248 cause of graft failure and patient death in heart transplant recipients.

249 , and incidence of cardiac adverse events in heart transplant recipients.

250 emains the leading cause of late death among heart transplant recipients.

251 ative right heart failure (RHF) in pediatric heart transplant recipients.

252 acardially and are, thus, maintained even in heart transplant recipients.

253 is suggests that statins improve survival in heart transplant recipients.

254 pathy (CAV) limits the lifespan of pediatric heart transplant recipients.

255 ancy is a major cause of death in orthotopic heart transplant recipients.

256 ves a reliable estimate of BP burden in most heart transplant recipients.

257 at an increased cost relative to nonbridged heart transplant recipients: $100 841more in costs and 1

258 , we performed a cross-sectional study of 72 heart transplant recipients: 40 with CAV and 32 without.

259 ecipients, 10 liver-transplant recipients, 5 heart-transplant recipients, 5 kidney and pancreas-trans

260 By means of the Spanish National Heart Transplant Registry database, we identified 704 ad

261 Nanoparticle macrophage PET-CT detects heart transplant rejection and predicts organ survival b

262 et and progression of clinically significant heart transplant rejection are currently monitored by se

263 pact the strength, phenotype, or kinetics of heart transplant rejection in mice and (b) does not impa

264 tion that is a leading reflection of chronic heart transplant rejection.

265 s of gene transcripts to refine diagnosis of heart transplant rejection.

266 IA(b+) fully allogeneic C57BL/6 (B6, H-2(b)) heart transplants resulted in donor-specific tolerance a

267 All-cause death or heart transplant served as a combined primary end point.

268 skin graft rejection and only a minority of heart transplants shows evidence of CAV.

269 h patients who underwent simultaneous kidney-heart transplant (SKH, n=252), primary kidney transplant

270 splanted for CHD from the combined Pediatric Heart Transplant Study (1993 to 2002, n = 367) and the C

271 patients (<18 years old) from the Pediatric Heart Transplant Study (PHTS) database listed for heart

272 Patients enrolled in the Pediatric Heart Transplant Study (PHTS) from 1996 to 2006 were str

273 This study reviewed Pediatric Heart Transplant Study data from 1993 to 2009.

274 iatric Cardiomyopathy Registry and Pediatric Heart Transplant Study was studied.

275 recipients from six centers in the Pediatric Heart Transplant Study were analyzed for time to RHC by

276 and 2009 at 35 institutions in the Pediatric Heart Transplant Study.

277 h EXCOR is comparable with overall pediatric heart transplant survival and superior to survival after

278 WT FR70 antibody significantly extended heart transplant survival to 19 days compared with untre

279 study sought to determine whether bridge-to-heart transplant survival with a TCS device is superior

280 Allogeneic heart transplants survived for 86.25+/-13.8, 46.3+/-4.6,

281 TLA4-Ig rejected fully MHC-mismatched BALB/c heart transplants, treatment of IL-6-deficient mice with

282 story of Kawasaki disease (KD) and pediatric heart transplant (TX) recipients.

283 Patients with a history of heart transplant undergoing dipyridamole rubidium-82 pos

284 h was to identify disparities in risk within heart transplant urgency designations.

285 Heart transplant volumes are not matching growing demand

286 Mortality and morbidity on the heart transplant waiting list have decreased.

287 number of new active adult candidates on the heart transplant waiting list increased by 19.2%.

288 rted and medically managed candidates on the heart transplant waiting list.

289 In 2011, the rate of pediatric heart transplants was 124.6 per 100 patient-years on the

290 The rejection of heart transplants was assessed histologically.

291 nce among patients receiving publicly funded heart transplants was associated with improved outcomes.

292 ber 2009, adult patients undergoing isolated heart transplant were prospectively classified as ECCT b

293 At 90 days, survival rates for heart transplants were 92.6% during the day vs 92.7% dur

294 The response of 4C T cells to skin and heart transplants were characterized.

295 8 years) recipients of primary, single-organ heart transplants were included.

296 Mouse heterotopic isograft heart transplants were performed in C57BL/6 mice treated

297 Syngeneic heart transplants were performed in mice deficient in CD

298 ate of rejection was seen in interval kidney-heart transplants when allografts shared partial antigen

299 8+/-8.19; P=0.025) but caused near-syngeneic heart transplants, which otherwise survived indefinitely

300 naesthetizing a patient who benefited from a heart transplant will undoubtedly fascinate any anaesthe